Acoltremon

Acoltremon
Molecular structure of acoltremon
3D representation of an acoltremon molecule
Clinical data
Trade namesTryptyr
Other namesAVX-012, WS-12
AHFS/Drugs.comMonograph
MedlinePlusa625071
License data
Routes of
administration
Eye drop
ATC code
  • None
Legal status
Legal status
Identifiers
  • (1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-propan-2-ylcyclohexane-1-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H27NO2
Molar mass289.419 g·mol−1
3D model (JSmol)
  • C[C@@H]1CC[C@H]([C@@H](C1)C(=O)NC2=CC=C(C=C2)OC)C(C)C
  • InChI=1S/C18H27NO2/c1-12(2)16-10-5-13(3)11-17(16)18(20)19-14-6-8-15(21-4)9-7-14/h6-9,12-13,16-17H,5,10-11H2,1-4H3,(H,19,20)/t13-,16+,17-/m1/s1
  • Key:HNSGVPAAXJJOPQ-XOKHGSTOSA-N

Acoltremon sold under the brand name Tryptyr, is a medication used for the treatment of dry eye syndrome. Acoltremon is a transient receptor potential melastatin 8 (TRPM8) thermoreceptor agonist. It is used as an eye drop.

The most common treatment-emergent adverse event experienced during the clinical studies was instillation site pain (burning or stinging) events.

Acoltremon was approved for medical use in the United States in May 2025. The US Food and Drug Administration considers it to be a first-in-class medication.